Delivering small interfering RNA for novel therapeutics

27Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The gene silencing capability of RNA interference (RNAi) is being used to study individual gene's biological function and role in biochemical pathways. However, the efficacy of RNAi depends upon efficient delivery of the intermediates of RNAi, small interfering RNA (siRNA) oligonucleotides. The delivery challenge is even greater when the aim is to inhibit the expression of target genes in disease tissues. In vivo delivery of siRNA is complicated and challenging, and recent works on various animal disease models and early successes in human clinical trials are enlightening the tremendous potential of RNAi therapeutics. In this chapter, the latest developments of in vivo delivery of siRNA and the critical issues related to this effort are addressed. © 2008 Humana Press.

Cite

CITATION STYLE

APA

Lu, P. Y., & Woodle, M. C. (2008). Delivering small interfering RNA for novel therapeutics. Methods in Molecular Biology, 437, 93–107. https://doi.org/10.1007/978-1-59745-210-6_3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free